KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Accumulated Expenses (2016 - 2025)

Quest Diagnostics (DGX) has disclosed Accumulated Expenses for 14 consecutive years, with $338.0 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 10.46% to $338.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $338.0 million through Dec 2025, up 10.46% year-over-year, with the annual reading at $338.0 million for FY2025, 10.46% up from the prior year.
  • Accumulated Expenses hit $338.0 million in Q4 2025 for Quest Diagnostics, up from $306.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $460.0 million in Q4 2021 to a low of $287.0 million in Q4 2023.
  • Historically, Accumulated Expenses has averaged $356.6 million across 5 years, with a median of $338.0 million in 2025.
  • Biggest five-year swings in Accumulated Expenses: grew 29.21% in 2021 and later decreased 26.79% in 2023.
  • Year by year, Accumulated Expenses stood at $460.0 million in 2021, then decreased by 14.78% to $392.0 million in 2022, then decreased by 26.79% to $287.0 million in 2023, then rose by 6.62% to $306.0 million in 2024, then rose by 10.46% to $338.0 million in 2025.
  • Business Quant data shows Accumulated Expenses for DGX at $338.0 million in Q4 2025, $306.0 million in Q4 2024, and $287.0 million in Q4 2023.